When comparing Viatris and Sarepta Therapeutics, Sarepta Therapeutics outperforms Viatris in 12 out of the 18 factors, including earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk, and profitability.